I was diagnosed with ADD and given Ritalin when I actually had Lyme (most of my symptoms up to that point were basic ADD, with some extra fatigue and other minor complaints), and the ritalin nearly killed me (seriously).
Hey Funk can you please expand how the Ritalin 'nearly killed' you? What would you recommend to minimise the chances of such problems happening for other people?One thing that western medicine is very proficient with is laboratory testing. Has he had any basic blood tests performed? Complete blood count, chemistry, metabolic profile, that sort of thing? If not you should strongly consider it, as these are important OBJECTIVE benchmarks of health that do not rely on mystic forces.
Yes if I had a kid with suspected ADHD before putting drugs and supplements into him/her, I would get thorough blood work and sleep studies done. The more money I had the more tests I would get. There are many conditions which could lead to similar symptoms as ADHD such as Lead poisoning, Iron deficiency (see
http://www.imminst.o...howtopic=19955), thyroid abnormalities, and sleep apnea (see below for examples). Even if there is not a complete resolution of the ADHD symptoms by treating the secondary problem (for example Sleep apnea), you are still likely to get some benefits for the kid's health and functioning. They will know they have that problem (often for the rest of their lives) and hopefully keep getting treated for it...
1: Thyroid. 1997 Jun;7(3):389-93.Links
Behavioral effects of liothyronine (L-T3) in children with attention deficit hyperactivity disorder in the presence and absence of resistance to thyroid hormone.
Weiss RE, Stein MA, Refetoff S.
Department of Medicine, The University of Chicago, IL 60637, USA.
Evidence that the thyroid may play a role in the pathogenesis of attention deficit hyperactivity disorder (ADHD) comes from observations that 48% to 73% of children with the syndrome of resistance to thyroid hormone (RTH) have ADHD. Casual observations in subjects with RTH have suggested that treatment with thyroid hormone may improve the symptoms of ADHD. The aim of this study was to determine whether thyroid hormone has a beneficial effect on the behavior of children with RTH. A prospective, randomized, double-blinded, placebo-controlled, cross-over study was conducted to evaluate the effect of the rapid acting thyroid hormone, liothyronine (L-T3), on the behavior of 8 children with ADHD + RTH, and 9 children with ADHD and normal thyroid function (ADHD Only). Parent and teacher ratings of hyperactivity (Conners scale) and a computerized continuous performance test (CPT) were used as objective measures of hyperactivity, attention and impulsivity. L-T3 had no effect on Conners Hyperactivity Index in 7 of 9 children with ADHD Only; it caused improvement and deterioration in 1 subject each. In contrast, the rating in 5 of 8 subjects with ADHD + RTH showed improvement, whereas 3 of 8 subjects remained unchanged. L-T3 was associated with increased commission errors in 5 of 8 children with ADHD Only and decreased commission errors in 4 of 7 with ADHD + RTH. In children with RTH and ADHD, particularly those that exhibit hyperactivity, L-T3 in supraphysiological doses may be beneficial in reducing hyperactivity and impulsivity. In the majority of children with ADHD who do not have RTH, L-T3 treatment has no effect or may be detrimental.
PMID: 9226208 [PubMed - indexed for MEDLINE]
1: Sleep Med. 2007 Jan;8(1):18-30. Epub 2006 Dec 6. Links
Attention-deficit/hyperactivity disorder with obstructive sleep apnea: a treatment outcome study.
Huang YS, Guilleminault C, Li HY, Yang CM, Wu YY, Chen NH.
Department of Child Psychiatry, Chang Gung Memorial University Hospital, Tao-Yuan, Taipei, Taiwan.
BACKGROUND: Children diagnosed with attention-deficit/hyperactivity disorder (ADHD), based on Diagnostic and Statistical Manual of Mental Disorders, Fourth edition (DSM-IV) criteria, may also have obstructive sleep apnea (OSA), but it is unclear whether treating OSA has similar results as methylphenidate (MPH), a commonly used treatment for ADHD. METHODS: This study enrolled 66 school-age children, referred for and diagnosed with ADHD, and 20 healthy controls. Polysomnography (PSG) performed after ADHD diagnosis showed the presence of mild OSA. After otolaryngological evaluation, parents and referring physicians of the children could select treatment of ADHD with MPH, treatment of OSA with adenotonsillectomy or no treatment. Systematic follow-up was performed six months after initiation of treatment, or diagnosis if no treatment. All children had pre- and post-clinical interviews; pediatric, neurologic, psychiatric and neurocognitive evaluation; PSG; ADHD rating scale, child behavior checklist (CBCL) filled out by parents and teacher; test of variables of attention (TOVA); and the quality of life in children with obstructive sleep disorder questionnaire (OSA-18). RESULTS: ADHD children had an apnea-hypopnea index (AHI)>1<5 event/hour; 27 were treated with MPH, 25 had adenotonsillectomy, and 14 had no treatment. The surgical and MPH groups improved more than the non-treatment group. When comparing MPH to post-surgery, the PSG and questionnaire sleep variables, some daytime symptoms (including attention span) and TOVA subscales (impulse control, response time and total ADHD score) improved more in the surgical group than the MPH group. The surgical group had an ADHD total score of 21.16+/-7.13 on the ADHD rating scale (ADHD-RS) post-surgery compared to 31.52+/-7.01 pre-surgery (p=0.0001), and the inattention and hyperactivity subscales were also significantly lower (p=0.0001). Finally, the results were significantly different between surgically and MPH-treated groups (ADHD-RS p=0.007). The surgical group also had a TOVA ADHD score lower than -1.8 and close to those obtained in normal controls. CONCLUSION: A low AHI score of >1 considered abnormal is detrimental to children with ADHD. Recognition and surgical treatment of underlying mild sleep-disordered breathing (SDB) in children with ADHD may prevent unnecessary long-term MPH usage and the potential side effects associated with drug intake.
PMID: 17157069 [PubMed - indexed for MEDLINE]